IVERIC Bio Inc (ISEE) Ordinary Shares
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company’s therapeutics portfolio consists of its clinical stage product candidate Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, its preclinical product candidate from its High temperature requirement A serine peptidase one protein (HtrA1), inhibitors program. Its lead gene therapy products also includes IC-100 and IC-200.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.